Correlation of melanoma gene expression score with clinical outcomes on a series of melanocytic lesions

A 23-gene expression signature was recently developed as an adjunct to histopathology to differentiate melanocytic nevi from melanoma. The current study correlated the gene expression signature scores to actual clinical outcomes in cases from the first validation study. RNA was extracted from 127 ar...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Human pathology 2019-04, Vol.86, p.213-221
Hauptverfasser: Ko, Jennifer S., Clarke, Loren E., Minca, Eugen C., Brown, Krystal, Flake, Darl D., Billings, Steven D.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 221
container_issue
container_start_page 213
container_title Human pathology
container_volume 86
creator Ko, Jennifer S.
Clarke, Loren E.
Minca, Eugen C.
Brown, Krystal
Flake, Darl D.
Billings, Steven D.
description A 23-gene expression signature was recently developed as an adjunct to histopathology to differentiate melanocytic nevi from melanoma. The current study correlated the gene expression signature scores to actual clinical outcomes in cases from the first validation study. RNA was extracted from 127 archival formalin-fixed paraffin-embedded tissue sections of melanocytic lesions. Gene expression was measured using quantitative reverse-transcription polymerase chain reaction, and a weighting algorithm was used to generate a numeric score. Gene expression test results were compared to histopathological diagnoses and development of local recurrence, sentinel lymph node metastases, and distant metastases. Sixty-five lesions were diagnosed histopathologically as melanoma. Fourteen developed metastases. Gene expression test results were malignant in 61 of 65 (93.8%) lesions (including all lesions that metastasized), indeterminate in 2 of 65 (3.1%) lesions, and benign in 2 of 65 (3.1%) lesions. The remaining 62 lesions were diagnosed as benign by histopathology. Gene expression test results were benign in 48 of 62 (77.4%), indeterminate in 7 of 62 (11.3%), and malignant in 7 of 62 (11.3%). There was a strong correlation between the gene expression signature test results and clinical outcomes. All lesions that metastasized were correctly identified by the test as malignant melanoma. •A 23-gene expression signature differentiates melanoma from nevi.•The gene signature correctly identified all melanomas that ultimately metastasized.•No lesion classified as benign by the gene signature recurred or metastasized.
doi_str_mv 10.1016/j.humpath.2018.12.001
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2159323115</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0046817718304878</els_id><sourcerecordid>2208676165</sourcerecordid><originalsourceid>FETCH-LOGICAL-c440t-48b406e4186b5e85ef4f3e182bfd878869334d8f1e81385bbfe0e3752e01da2b3</originalsourceid><addsrcrecordid>eNqFkUtr3DAUhUVpaSaPn9Ai6CYbO7p6WbMqZcgLAtm0a2HL1xkNtjWV7Cb595WZSRfdZKUL9ztHl3MI-QKsBAb6aldu52FfT9uSMzAl8JIx-EBWoAQvjFjzj2TFmNSFgao6Iacp7TIASqrP5EQwpbVZyxV52oQYsa8nH0YaOjrkeQxDTZ9wRIov-4gpLbvkQkT67Kctdb0fvat7GubJhQETzfuaJox-md9M3OvkHe1xkadz8qmr-4QXx_eM_Lq5_rm5Kx4eb-83Px4KJyWbCmkayTRKMLpRaBR2shMIhjddaypj9FoI2ZoO0IAwqmk6ZCgqxZFBW_NGnJHLg-8-ht8zpskOPjns80EY5mQ5qLXgIgeR0W__obswxzFfZzlnRlca9EKpA-ViSCliZ_fRD3V8tcDs0oTd2WMTdmnCArc56Kz7enSfmwHbf6q36DPw_QBgjuOPx2iT8zg6bH1EN9k2-He--AvOmZ1N</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2208676165</pqid></control><display><type>article</type><title>Correlation of melanoma gene expression score with clinical outcomes on a series of melanocytic lesions</title><source>ScienceDirect Freedom Collection (Elsevier)</source><creator>Ko, Jennifer S. ; Clarke, Loren E. ; Minca, Eugen C. ; Brown, Krystal ; Flake, Darl D. ; Billings, Steven D.</creator><creatorcontrib>Ko, Jennifer S. ; Clarke, Loren E. ; Minca, Eugen C. ; Brown, Krystal ; Flake, Darl D. ; Billings, Steven D.</creatorcontrib><description>A 23-gene expression signature was recently developed as an adjunct to histopathology to differentiate melanocytic nevi from melanoma. The current study correlated the gene expression signature scores to actual clinical outcomes in cases from the first validation study. RNA was extracted from 127 archival formalin-fixed paraffin-embedded tissue sections of melanocytic lesions. Gene expression was measured using quantitative reverse-transcription polymerase chain reaction, and a weighting algorithm was used to generate a numeric score. Gene expression test results were compared to histopathological diagnoses and development of local recurrence, sentinel lymph node metastases, and distant metastases. Sixty-five lesions were diagnosed histopathologically as melanoma. Fourteen developed metastases. Gene expression test results were malignant in 61 of 65 (93.8%) lesions (including all lesions that metastasized), indeterminate in 2 of 65 (3.1%) lesions, and benign in 2 of 65 (3.1%) lesions. The remaining 62 lesions were diagnosed as benign by histopathology. Gene expression test results were benign in 48 of 62 (77.4%), indeterminate in 7 of 62 (11.3%), and malignant in 7 of 62 (11.3%). There was a strong correlation between the gene expression signature test results and clinical outcomes. All lesions that metastasized were correctly identified by the test as malignant melanoma. •A 23-gene expression signature differentiates melanoma from nevi.•The gene signature correctly identified all melanomas that ultimately metastasized.•No lesion classified as benign by the gene signature recurred or metastasized.</description><identifier>ISSN: 0046-8177</identifier><identifier>EISSN: 1532-8392</identifier><identifier>DOI: 10.1016/j.humpath.2018.12.001</identifier><identifier>PMID: 30566894</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Biopsy ; Clinical outcomes ; Gene expression ; Gene expression signature ; Histopathology ; Hybridization ; Lymphatic system ; Melanoma ; Metastasis ; Nevi ; Skin cancer ; Tumors</subject><ispartof>Human pathology, 2019-04, Vol.86, p.213-221</ispartof><rights>2018 Myriad Genetics, Inc.</rights><rights>Copyright © 2018 Myriad Genetics, Inc. Published by Elsevier Inc. All rights reserved.</rights><rights>2018. Myriad Genetics, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c440t-48b406e4186b5e85ef4f3e182bfd878869334d8f1e81385bbfe0e3752e01da2b3</citedby><cites>FETCH-LOGICAL-c440t-48b406e4186b5e85ef4f3e182bfd878869334d8f1e81385bbfe0e3752e01da2b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.humpath.2018.12.001$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30566894$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ko, Jennifer S.</creatorcontrib><creatorcontrib>Clarke, Loren E.</creatorcontrib><creatorcontrib>Minca, Eugen C.</creatorcontrib><creatorcontrib>Brown, Krystal</creatorcontrib><creatorcontrib>Flake, Darl D.</creatorcontrib><creatorcontrib>Billings, Steven D.</creatorcontrib><title>Correlation of melanoma gene expression score with clinical outcomes on a series of melanocytic lesions</title><title>Human pathology</title><addtitle>Hum Pathol</addtitle><description>A 23-gene expression signature was recently developed as an adjunct to histopathology to differentiate melanocytic nevi from melanoma. The current study correlated the gene expression signature scores to actual clinical outcomes in cases from the first validation study. RNA was extracted from 127 archival formalin-fixed paraffin-embedded tissue sections of melanocytic lesions. Gene expression was measured using quantitative reverse-transcription polymerase chain reaction, and a weighting algorithm was used to generate a numeric score. Gene expression test results were compared to histopathological diagnoses and development of local recurrence, sentinel lymph node metastases, and distant metastases. Sixty-five lesions were diagnosed histopathologically as melanoma. Fourteen developed metastases. Gene expression test results were malignant in 61 of 65 (93.8%) lesions (including all lesions that metastasized), indeterminate in 2 of 65 (3.1%) lesions, and benign in 2 of 65 (3.1%) lesions. The remaining 62 lesions were diagnosed as benign by histopathology. Gene expression test results were benign in 48 of 62 (77.4%), indeterminate in 7 of 62 (11.3%), and malignant in 7 of 62 (11.3%). There was a strong correlation between the gene expression signature test results and clinical outcomes. All lesions that metastasized were correctly identified by the test as malignant melanoma. •A 23-gene expression signature differentiates melanoma from nevi.•The gene signature correctly identified all melanomas that ultimately metastasized.•No lesion classified as benign by the gene signature recurred or metastasized.</description><subject>Biopsy</subject><subject>Clinical outcomes</subject><subject>Gene expression</subject><subject>Gene expression signature</subject><subject>Histopathology</subject><subject>Hybridization</subject><subject>Lymphatic system</subject><subject>Melanoma</subject><subject>Metastasis</subject><subject>Nevi</subject><subject>Skin cancer</subject><subject>Tumors</subject><issn>0046-8177</issn><issn>1532-8392</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNqFkUtr3DAUhUVpaSaPn9Ai6CYbO7p6WbMqZcgLAtm0a2HL1xkNtjWV7Cb595WZSRfdZKUL9ztHl3MI-QKsBAb6aldu52FfT9uSMzAl8JIx-EBWoAQvjFjzj2TFmNSFgao6Iacp7TIASqrP5EQwpbVZyxV52oQYsa8nH0YaOjrkeQxDTZ9wRIov-4gpLbvkQkT67Kctdb0fvat7GubJhQETzfuaJox-md9M3OvkHe1xkadz8qmr-4QXx_eM_Lq5_rm5Kx4eb-83Px4KJyWbCmkayTRKMLpRaBR2shMIhjddaypj9FoI2ZoO0IAwqmk6ZCgqxZFBW_NGnJHLg-8-ht8zpskOPjns80EY5mQ5qLXgIgeR0W__obswxzFfZzlnRlca9EKpA-ViSCliZ_fRD3V8tcDs0oTd2WMTdmnCArc56Kz7enSfmwHbf6q36DPw_QBgjuOPx2iT8zg6bH1EN9k2-He--AvOmZ1N</recordid><startdate>201904</startdate><enddate>201904</enddate><creator>Ko, Jennifer S.</creator><creator>Clarke, Loren E.</creator><creator>Minca, Eugen C.</creator><creator>Brown, Krystal</creator><creator>Flake, Darl D.</creator><creator>Billings, Steven D.</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>201904</creationdate><title>Correlation of melanoma gene expression score with clinical outcomes on a series of melanocytic lesions</title><author>Ko, Jennifer S. ; Clarke, Loren E. ; Minca, Eugen C. ; Brown, Krystal ; Flake, Darl D. ; Billings, Steven D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c440t-48b406e4186b5e85ef4f3e182bfd878869334d8f1e81385bbfe0e3752e01da2b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Biopsy</topic><topic>Clinical outcomes</topic><topic>Gene expression</topic><topic>Gene expression signature</topic><topic>Histopathology</topic><topic>Hybridization</topic><topic>Lymphatic system</topic><topic>Melanoma</topic><topic>Metastasis</topic><topic>Nevi</topic><topic>Skin cancer</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ko, Jennifer S.</creatorcontrib><creatorcontrib>Clarke, Loren E.</creatorcontrib><creatorcontrib>Minca, Eugen C.</creatorcontrib><creatorcontrib>Brown, Krystal</creatorcontrib><creatorcontrib>Flake, Darl D.</creatorcontrib><creatorcontrib>Billings, Steven D.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Human pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ko, Jennifer S.</au><au>Clarke, Loren E.</au><au>Minca, Eugen C.</au><au>Brown, Krystal</au><au>Flake, Darl D.</au><au>Billings, Steven D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Correlation of melanoma gene expression score with clinical outcomes on a series of melanocytic lesions</atitle><jtitle>Human pathology</jtitle><addtitle>Hum Pathol</addtitle><date>2019-04</date><risdate>2019</risdate><volume>86</volume><spage>213</spage><epage>221</epage><pages>213-221</pages><issn>0046-8177</issn><eissn>1532-8392</eissn><abstract>A 23-gene expression signature was recently developed as an adjunct to histopathology to differentiate melanocytic nevi from melanoma. The current study correlated the gene expression signature scores to actual clinical outcomes in cases from the first validation study. RNA was extracted from 127 archival formalin-fixed paraffin-embedded tissue sections of melanocytic lesions. Gene expression was measured using quantitative reverse-transcription polymerase chain reaction, and a weighting algorithm was used to generate a numeric score. Gene expression test results were compared to histopathological diagnoses and development of local recurrence, sentinel lymph node metastases, and distant metastases. Sixty-five lesions were diagnosed histopathologically as melanoma. Fourteen developed metastases. Gene expression test results were malignant in 61 of 65 (93.8%) lesions (including all lesions that metastasized), indeterminate in 2 of 65 (3.1%) lesions, and benign in 2 of 65 (3.1%) lesions. The remaining 62 lesions were diagnosed as benign by histopathology. Gene expression test results were benign in 48 of 62 (77.4%), indeterminate in 7 of 62 (11.3%), and malignant in 7 of 62 (11.3%). There was a strong correlation between the gene expression signature test results and clinical outcomes. All lesions that metastasized were correctly identified by the test as malignant melanoma. •A 23-gene expression signature differentiates melanoma from nevi.•The gene signature correctly identified all melanomas that ultimately metastasized.•No lesion classified as benign by the gene signature recurred or metastasized.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>30566894</pmid><doi>10.1016/j.humpath.2018.12.001</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0046-8177
ispartof Human pathology, 2019-04, Vol.86, p.213-221
issn 0046-8177
1532-8392
language eng
recordid cdi_proquest_miscellaneous_2159323115
source ScienceDirect Freedom Collection (Elsevier)
subjects Biopsy
Clinical outcomes
Gene expression
Gene expression signature
Histopathology
Hybridization
Lymphatic system
Melanoma
Metastasis
Nevi
Skin cancer
Tumors
title Correlation of melanoma gene expression score with clinical outcomes on a series of melanocytic lesions
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T06%3A12%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Correlation%20of%20melanoma%20gene%20expression%20score%20with%20clinical%20outcomes%20on%20a%20series%20of%20melanocytic%20lesions&rft.jtitle=Human%20pathology&rft.au=Ko,%20Jennifer%20S.&rft.date=2019-04&rft.volume=86&rft.spage=213&rft.epage=221&rft.pages=213-221&rft.issn=0046-8177&rft.eissn=1532-8392&rft_id=info:doi/10.1016/j.humpath.2018.12.001&rft_dat=%3Cproquest_cross%3E2208676165%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2208676165&rft_id=info:pmid/30566894&rft_els_id=S0046817718304878&rfr_iscdi=true